Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MYXDfZRwfG:6aXOgRZN{[Xl? MVuxNEBvVQ>? NEDBVII4OiCq NWjY[FRZTE2VTx?= MkjaVI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 M{PtZ|I1QTByOEez
HT-29 MnXER5l1d3SxeHnjJGF{e2G7 NFGyb4IyOCCwTR?= NFfZeog4OiCq MkXSSG1UVw>? M1PT[XBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= NV:4WXRLOjR7MEC4O|M>
HT-29 NUfXfXhoS3m2b4TvfIlkKEG|c3H5 Mnj5NVAhdk1? NUOz[FFZPzJiaB?= MmfNSG1UVw>? NIj3enVRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NXfUPY84OjR7MEC4O|M>
PC3 NVjRVGFEU2mwYYPlJGF{e2G7 NFryXoYyODBibl2= NX\ERVlyOSCq NIfaRVNFVVOR M1;KOXBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u MUmyNVk4QDZ6Mx?=
PC3 M4iwZWtqdmG|ZTDBd5NigQ>? MlTqNVAxKG6P M3O5[FEhcA>? NEnjVHpFVVOR MoTsSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NGDmT5gzOTl5OE[4Ny=>
PC3 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[5WoU6OS53IN88US=> NUDFPZVrOSCq M4OwNmROW09? M1Xid2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NFG1fFYzOTl5OE[4Ny=>
HEK293 M2\oWGZ2dmO2aX;uJGF{e2G7 M4rHb|ExOCCwTR?= NEXS[GE5KGh? NWPHZ|Q5TE2VTx?= NIO2U4tKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NY\PN|M2OjF3M{mzNFE>
BT-20 M{WzcGtqdmG|ZTDBd5NigQ>? NFGwNWkzOCEQvF2= MWrEUXNQ NXTjTFE3TG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36= M{fMNVIyOzV|NUWx
U937 NIrBUnVCdnSrYnHjeIVzcWGuIFHzd4F6 NGnscGo2OCEQvF2= NIHuPYE1QCCq Mk\sSG1UVw>? MnX0TY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| MnX2NlEyPDJzME[=
U937 NVvmdpNMSW62aXLhZ5RmemmjbDDBd5NigQ>? MlzTOVAh|ryP M{foZ|Q5KGh? NH\VflhFVVOR NInYWIdFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| M33ab|IyOTR{MUC2
U937 MoS1RY51cWKjY4TldolidCCDc4PhfS=> MkTmOVAh|ryP Mom0OFghcA>? NHz5[phFVVOR NFzOO3JFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? NVu2XVliOjFzNEKxNFY>
MCF-7 MmPoRZV1d3CqYXf5JGF{e2G7 MUSzNEBvVQ>? M1znblQhcA>? NFnIWHBFVVOR M2nIbmlv\HWlZYOgZZV1d3CqYXf5 NY\PU5B3OjByMkixN|Q>
U87MG NX\odog4U2mwYYPlJGF{e2G7 NEPhbJAyKM7:TR?= MWK2JIg> NIT3eYdFVVOR MlmwVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? MUWxPVg1QDRyNB?=
U87MG NE\z[4lMcW6jc3WgRZN{[Xl? NFPxSlEyKM7:TR?= MknYOkBp MVjEUXNQ MXfQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= MX2xPVg1QDRyNB?=
U87MG NVr2NXVJU2mwYYPlJGF{e2G7 M13lXFEh|ryP M2i1OFYhcA>? M1zS[WROW09? M{HmbWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w M4TLWFE6QDR6NEC0
U87MG NFHGXG1McW6jc3WgRZN{[Xl? NHPBSnYyKM7:TR?= NFzHboo3KGh? M3;qUWROW09? Ml72SI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v MUCxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb NUPo[o06SXW2b4DoZYd6KEG|c3H5 M4DPOlAvOiEQvF2= MXWyOEBp NEnocIxFVVOR NULwbYh7UW6mdXPld{BifXSxcHjh[5k> NV\BfYNLOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NG\Wc4tCfXSxcHjh[5khSXO|YYm= MoDwNE4zKM7:TR?= MYmyOEBp M13CdWROW09? NGLnfoVKdmS3Y3XzJIF2fG:yaHHnfS=> NFvsXIkyQDN7MUm0PS=>
H4 MV7GeY5kfGmxbjDBd5NigQ>? NYDkXXViOC5{IN88US=> Mm\PNlQhcA>? M4jmOGROW09? NI[3OJNKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ NF\nZ|kyQDB{NEW4OC=>
HeLa NWjwcXdlTnWwY4Tpc44hSXO|YYm= NIjYW2QyODBibl2= M3TpdFM3KGh? M{jHU2ROW09? M4HHeWlv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> M3XxN|E4PTZ|M{i1
HeLa NHrQRnJHfW6ldHnvckBCe3OjeR?= MkX1NVAxKG6P MWezOkBp NXiwepJnTE2VTx?= MmPsTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NWLqO3doOTd3NkOzPFU>
HeLa MX3GeY5kfGmxbjDBd5NigQ>? MkSxNVAxKG6P MXmzOkBp MWLEUXNQ NGLTWWJKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NVL3RVg2OTd3NkOzPFU>
SYF M{ntV2Z2dmO2aX;uJGF{e2G7 MXOxNFAhdk1? M{HKZ|I1KGh? MX;EUXNQ MX3JcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= MW[xO|U3OzN6NR?=
SYF NFXEV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn60NVAxKG6P NICwUmEzPCCq M4i2WGROW09? NED4fXFKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz NUf4R2lYOTd3NkOzPFU>
HEK293T NIf4VZFCdnSrdnnyZYwhSXO|YYm= M1njOVEhdk1? Mnu5OEBl M1rnZmROW09? NUSzeWY4UW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> Mn\iNVc1QDV3MEG=
HEK293T MXzBcpRqfmm{YXygRZN{[Xl? NWLKe4pZOSCwTR?= NHPmT3A1KGR? NF3uO4NFVVOR M17IRmlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N NFj6S3oyPzR6NUWwNS=>
PBMC MUfGeY5kfGmxbjDBd5NigQ>? MVSxJI5O M4C5T|E1KGR? MorQSG1UVw>? MlW3VoVlfWOnczDDR3I2KGSnboPpeJk> NX:2TWFSOTd2OEW1NFE>
PBMC M4m2fWZ2dmO2aX;uJGF{e2G7 Mk\zNUBvVQ>? MXyxOEBl Mlj4SG1UVw>? NVPvfldETG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? NGfVdFEyPzR6NUWwNS=>
HEK293 cells NYnEZ2J2U2mwYYPlJGF{e2G7 MVy1NEBvVQ>? MYW0OUBucW5? MnfsSG1UVw>? MX;Jcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O MVixO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc M13vfmZ2dmO2aX;uJGF{e2G7 NXTVfmluOTByIH7N MYC0JIg> Mo\vSG1UVw>? MnPlTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM> M1nYdlE4OTJ6Mk[y
Human mixed lymphocyte NGXpfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmwOUBvVQ>? NXfXZlJbTE2VTx?= MXHJR|UxRTFwNjDuUU4> NY\TbHJTOTZzOEW4OlU>
Lewis rat lymph node cells MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHYXnBvPSEQvF2= NGTP[3dFVVOR MoDGTWM2OD1{Lk[g{txO MnLDNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice NELkRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6wO2xLOTBibl2= MnzmO|IhcA>? MYXEUXNQ Ml7sTY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?= MY[xNFAzOTl2OB?=
MRK-nu-1 NIPOWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfJTWM2OD1yLki0OUBxVQ>? NWrtepVOW0GQR1XS
OCUB-M MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjuXolKSzVyPUWuNlQheE1? NGnU[2dUSU6JRWK=
SF539 M4fuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFzLk[gdG0> M2HmeHNCVkeHUh?=
ES4 Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJzLkWgdG0> MmrZV2FPT0WU
RL95-2 NH7DWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjvfo1WUUN3ME2xNFcheE1? M2rrenNCVkeHUh?=
LC-2-ad MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\2d|lKSzVyPUSyN{BxVQ>? MnL4V2FPT0WU
Daudi MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjoTWM2OD12M{SgdG0> M1vH[3NCVkeHUh?=
NTERA-S-cl-D1 M1LpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:4NGlEPTB;NESzJJBO NUXrS3lxW0GQR1XS
OS-RC-2 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTZ3MjDwUS=> MlrVV2FPT0WU
VA-ES-BJ M{fUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTd{MzDwUS=> MUjTRW5ITVJ?
GR-ST MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX2RYpKSzVyPUi0OkBxVQ>? M2T3WHNCVkeHUh?=
SW872 NX\YOldQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3yb4RKSzVyPUi0OkBxVQ>? NUP3TGs{W0GQR1XS
NOS-1 NV3CW|ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jFW2lEPTB;OEexJJBO MoHkV2FPT0WU
MC116 NIrpbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml30TWM2OD17OEWgdG0> NIXMXlVUSU6JRWK=
NCI-H1355 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH4TWM2OD1zLkCxJI5O Mn23V2FPT0WU
RPMI-8226 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[zWYVKSzVyPUGuNVkhdk1? NUH0dFJrW0GQR1XS
TE-15 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zpR2lEPTB;MT6zOkBvVQ>? MWnTRW5ITVJ?
Ramos-2G6-4C10 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHJTXhKSzVyPUGuOFYhdk1? M36yPHNCVkeHUh?=
KU812 NXXrSoptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7LTWM2OD1{LkCxJI5O NGHQenNUSU6JRWK=
EW-1 NFr4codIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\GfWlEPTB;Mj6xO{BvVQ>? M4i5SXNCVkeHUh?=
KS-1 M{PKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfDNVBOUUN3ME2yMlQ2KG6P M{\pfHNCVkeHUh?=
SK-LMS-1 M3nKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJwNEmgcm0> M3zwZ3NCVkeHUh?=
TGBC1TKB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[wOnJPUUN3ME2yMlY6KG6P NHiwO5VUSU6JRWK=
TE-6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJwN{egcm0> MVPTRW5ITVJ?
ETK-1 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXsSoZGUUN3ME2yMlgzKG6P MULTRW5ITVJ?
BE-13 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDtOo9KSzVyPUKuPVkhdk1? NXm4SXBKW0GQR1XS
A3-KAW NVPvdYJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzZdItKSzVyPUKuPVkhdk1? MX\TRW5ITVJ?
TE-10 M2r6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLPTWM2OD1|LkOgcm0> M2L2fHNCVkeHUh?=
DOHH-2 NFWxVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\PTFJKSzVyPUOuN|Uhdk1? M1z3dnNCVkeHUh?=
ES6 M17MU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X1W2lEPTB;Mz60N{BvVQ>? MXvTRW5ITVJ?
OPM-2 NXvTXYoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrjb4Z{UUN3ME20MlE2KG6P NVPZXI1KW0GQR1XS
SH-4 NI\PbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDx[3FmUUN3ME20MlM1KG6P MkfTV2FPT0WU
NB13 NFjITI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXIcoFKSzVyPUSuN|Yhdk1? NGnxWWNUSU6JRWK=
HUTU-80 NFGxRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLSWHhKSzVyPUSuOFIhdk1? MXXTRW5ITVJ?
CCRF-CEM NH7oZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7qTWM2OD12Lkm0JI5O Mlr6V2FPT0WU
TGBC24TKB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPqNI1FUUN3ME21MlUyKG6P NFLkclRUSU6JRWK=
697 NX3VXXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHITWM2OD14LkK4JI5O MXTTRW5ITVJ?
J-RT3-T3-5 NIS2cnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHETWM2OD14LkS2JI5O NHPvS3lUSU6JRWK=
KALS-1 M13HUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvoUWh6UUN3ME22MlU3KG6P NX7Eb4FwW0GQR1XS
no-10 NY\NOGgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTdwMkmgcm0> MX7TRW5ITVJ?
SK-NEP-1 NVrsdZpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm2TWM2OD16Lke5JI5O MWjTRW5ITVJ?
L-540 M3;4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO5eGFpUUN3ME2xNE41OiCwTR?= NXPWemttW0GQR1XS
JiyoyeP-2003 NWPNcI9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3FTWM2OD1zMD65OEBvVQ>? M1jCUHNCVkeHUh?=
HH NHnhWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfpXnhKSzVyPUGxMlM6KG6P NYDoc5hwW0GQR1XS
SR MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HMR2lEPTB;MUGuOFUhdk1? MoPzV2FPT0WU
QIMR-WIL NVrycJl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV34fo5qUUN3ME2xNU45PSCwTR?= MWrTRW5ITVJ?
A4-Fuk Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfsTWM2OD1zMz6xNkBvVQ>? MoHwV2FPT0WU
CESS NYO2d41ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LsWWlEPTB;MUOuNVMhdk1? Mlz2V2FPT0WU
KE-37 NF\qUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP6TWM2OD1zNj6wO{BvVQ>? MVXTRW5ITVJ?
SK-UT-1 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrX[INKSzVyPUG2MlgyKG6P MXjTRW5ITVJ?
SIG-M5 NGHvV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nzdWlEPTB;MUeuNlUhdk1? MV3TRW5ITVJ?
HT NX\nT3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzhUmJKSzVyPUG3MlYhdk1? NYPZ[mxOW0GQR1XS
DEL M3XTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF5Lkm5JI5O MUjTRW5ITVJ?
SK-PN-DW Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJyLkKzJI5O MnHBV2FPT0WU
RPMI-8402 M4fHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJzLke3JI5O NX;mPGR7W0GQR1XS
RPMI-6666 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnT[XZzUUN3ME2yOE41OiCwTR?= NXXxbo03W0GQR1XS
NCI-H720 NF\oVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTjSoszUUN3ME2yOU41OSCwTR?= NI\G[4tUSU6JRWK=
EW-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfsRZVKSzVyPUK2Mlg4KG6P NWjPOoVmW0GQR1XS
BL-70 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPtTWM2OD1{OD6zPEBvVQ>? MXPTRW5ITVJ?
SF126 NHj2[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrldpRKSzVyPUOwMlM5KG6P MX3TRW5ITVJ?
BC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrPTIw4UUN3ME2zNU4zPiCwTR?= M2\wW3NCVkeHUh?=
MHH-PREB-1 M13xUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqycYZKSzVyPUOyMlQ1KG6P MVLTRW5ITVJ?
A101D MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HxUWlEPTB;M{KuOlIhdk1? M1H6N3NCVkeHUh?=
NMC-G1 NYHRcZhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN|Lk[3JI5O MX3TRW5ITVJ?
LB1047-RCC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPJbnVKUUN3ME2zOE43QSCwTR?= NIrqeYJUSU6JRWK=
EM-2 MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW0e2FKSzVyPUO4MlU{KG6P NFTIXY5USU6JRWK=
COLO-684 NILnPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\5SIFTUUN3ME2zPU45KG6P NWTJXFk{W0GQR1XS
Becker M1G1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrEZ4l{UUN3ME20NU4xPSCwTR?= M2npZ3NCVkeHUh?=
BL-41 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LDRmlEPTB;NEOuOlYhdk1? NHvXZ3JUSU6JRWK=
MDA-MB-134-VI NF;M[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTR2LkCyJI5O NEK1XXVUSU6JRWK=
L-363 MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGxNphFUUN3ME20OE44OyCwTR?= MVjTRW5ITVJ?
ECC4 NV3ve2pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HpfWlEPTB;NESuO|ghdk1? MVLTRW5ITVJ?
A388 M1T0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT1Zmd6UUN3ME20OE45OiCwTR?= MkPNV2FPT0WU
HEL NYjEe4dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDHVJRKSzVyPUS5Mlc6KG6P MVnTRW5ITVJ?
RKO M3njS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTVyLkK5JI5O MUnTRW5ITVJ?
KINGS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnpWIRZUUN3ME21NU42PSCwTR?= MVLTRW5ITVJ?
EB-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\NOXB[UUN3ME21Nk43PyCwTR?= NYfido9HW0GQR1XS
ARH-77 NV7WUI44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjiZY9JUUN3ME21Nk45KG6P MoDKV2FPT0WU
GCIY NHHCVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTV|LkS2JI5O NXfnVYxQW0GQR1XS
NCI-H1304 NUjrbmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXoNXY3UUN3ME21O{4zOiCwTR?= NULlTXJ7W0GQR1XS
KARPAS-299 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[2eGlEPTB;NkGuPFIhdk1? MoDVV2FPT0WU
IA-LM M3XC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;KTWM2OD14OD6xN{BvVQ>? NH3VSHRUSU6JRWK=
GI-1 NIWyfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv5cnQzUUN3ME23NE4{QSCwTR?= NIT3UY9USU6JRWK=
TE-11 M4Hr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfJTWM2OD15Nz6xO{BvVQ>? MV;TRW5ITVJ?
LS-411N NFzFOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfkTYtKSzVyPUe3MlU4KG6P MkHtV2FPT0WU
no-11 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr2Z29ZUUN3ME24N{4zPCCwTR?= MYPTRW5ITVJ?
MV-4-11 NWr1NZN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLsdWFKSzVyPUizMlc{KG6P M4rSPHNCVkeHUh?=
BV-173 NUnURoliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPwTWM2OD16Mz65O{BvVQ>? MWjTRW5ITVJ?
CMK NYO1[pNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInkeY5KSzVyPUi0MlE3KG6P MnnrV2FPT0WU
LC4-1 NIXRWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrKO3pLUUN3ME24Ok44OiCwTR?= MoPwV2FPT0WU
COR-L279 NXTR[Yd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTh5LkK1JI5O NVLzcJVmW0GQR1XS
NCI-H209 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrPNIFMUUN3ME24O{41OSCwTR?= NFvTR2RUSU6JRWK=
Raji M4H2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTh7LkeyJI5O MXzTRW5ITVJ?
LB996-RCC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTl|LkSzJI5O MoPXV2FPT0WU
NCI-H526 M4OwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnVNZNKSzVyPUmzMlU6KG6P NWDXbWlXW0GQR1XS
KGN NUWyO|hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnhdWdOUUN3ME25Ok4zQSCwTR?= NVP1WW5vW0GQR1XS
MOLT-4 NX;EPFZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn0SmpKSzVyPUm2Mlc6KG6P MWPTRW5ITVJ?
PF-382 M3;1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf0TWM2OD17Nj63PUBvVQ>? MV7TRW5ITVJ?
BC-3 M1TqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDOTWM2OD17OT6xPEBvVQ>? NELkfJhUSU6JRWK=
KARPAS-422 NWq0SXF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHCTWM2OD1zMEKuNFkhdk1? MkXLV2FPT0WU
SBC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXETWM2OD1zMEeuO|Uhdk1? MYTTRW5ITVJ?
LC-1F M2HLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILzOFNKSzVyPUGwPE4xPSCwTR?= MXXTRW5ITVJ?
GB-1 NFjyNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;6cIZKSzVyPUGwPU4xOiCwTR?= NFrsVmxUSU6JRWK=
SNB75 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjhTZNKSzVyPUGxPU43QSCwTR?= MWjTRW5ITVJ?
BB65-RCC NGTUcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkewTWM2OD1zMUmuPVMhdk1? NVLKZo9bW0GQR1XS
NCI-N87 NE\Hb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF{MT65PEBvVQ>? NFP3R2xUSU6JRWK=
IST-MEL1 M1HOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13EbGlEPTB;MUKyMlM5KG6P M1\Rd3NCVkeHUh?=
HOP-62 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT6bG9ZUUN3ME2xNlYvQDlibl2= NUHHbmNIW0GQR1XS
ACN Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyzV3hKSzVyPUG0Ok44PSCwTR?= M2TqWHNCVkeHUh?=
DMS-114 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF3MD62O{BvVQ>? M1;hcXNCVkeHUh?=
MLMA MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXDTWM2OD1zNUmuPFghdk1? MV3TRW5ITVJ?
HT-144 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF4NT60N{BvVQ>? NVezcFBKW0GQR1XS
C2BBe1 NWLSd2VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXMUJJrUUN3ME2xOlcvPzZibl2= M3\kVHNCVkeHUh?=
L-428 MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjafY55UUN3ME2xO|cvPyCwTR?= NGCzcHZUSU6JRWK=
DU-4475 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF6Nz62PEBvVQ>? NEG1fldUSU6JRWK=
CP67-MEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3raVmlEPTB;MUm5MlM5KG6P MXrTRW5ITVJ?
MEG-01 NIPiboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTpXZM6UUN3ME2yNFEvQTZibl2= M4OweXNCVkeHUh?=
IST-SL2 NELCdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny1TWM2OD1{MEiuOlMhdk1? NX7rfmtxW0GQR1XS
ES8 M2rxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ{NT65OEBvVQ>? NHrwb|dUSU6JRWK=
COLO-800 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[yTWM2OD1{M{WuNlghdk1? MVvTRW5ITVJ?
MFH-ino M2TrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13VWGlEPTB;MkO1Mlg1KG6P M3ju[3NCVkeHUh?=
OVCAR-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;Y[nlKSzVyPUKzO{4zPCCwTR?= NYroNJFOW0GQR1XS
PSN1 M3qwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjMPJJKSzVyPUK0Nk44OSCwTR?= MlTmV2FPT0WU
EW-12 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfFT21KSzVyPUK0N{4yKG6P M2LkUXNCVkeHUh?=
HCC1599 MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL2[mx{UUN3ME2yOlEvPDdibl2= MoX2V2FPT0WU
SJSA-1 NY[5S3o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ5MT60OkBvVQ>? MmruV2FPT0WU
ST486 M2Lx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\HfGlEPTB;Mkm2MlE1KG6P NF3yTXhUSU6JRWK=
NOMO-1 M4S3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknlTWM2OD1|MECuNlEhdk1? NH;0VJBUSU6JRWK=
MN-60 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknWTWM2OD1|MEWuN|Ihdk1? M4mzSnNCVkeHUh?=
HCC1187 NHruXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHhOHBPUUN3ME2zNFcvOjVibl2= M3fKSnNCVkeHUh?=
SW982 NGXQeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX0SoxKSzVyPUOxOE44PSCwTR?= NITXWnhUSU6JRWK=
LB647-SCLC NUXTNXRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfJZ5NWUUN3ME2zNlgvPzFibl2= M{ezdXNCVkeHUh?=
HC-1 M1j1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LpemlEPTB;M{O1MlUhdk1? NUHTS4ViW0GQR1XS
EHEB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzpbpZRUUN3ME2zN|cvPTJibl2= MoDZV2FPT0WU
TUR MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nPc2lEPTB;M{[zMlk2KG6P MXjTRW5ITVJ?
LU-139 NGSzTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D2bWlEPTB;M{e4MlAzKG6P MV7TRW5ITVJ?
NB1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTN6ND60OUBvVQ>? NWTKNmdRW0GQR1XS
BB30-HNC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LkW2lEPTB;M{i4MlMzKG6P MUDTRW5ITVJ?
HAL-01 M{TBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vh[WlEPTB;M{i5MlI3KG6P NHHoO3dUSU6JRWK=
K5 NWPZNZRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnjN5pKSzVyPUSxNU4{PyCwTR?= MUnTRW5ITVJ?
MZ2-MEL NELUV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTRzMz62OEBvVQ>? M{PWZnNCVkeHUh?=
RXF393 M4DEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXCTWM2OD12MU[uOFUhdk1? MorMV2FPT0WU
NCI-H1648 NVO5dVc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPrfZhKSzVyPUSxO{42OyCwTR?= NEftSnRUSU6JRWK=
TE-12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe5VmJKSzVyPUSzOE4zPiCwTR?= M4rlO3NCVkeHUh?=
EoL-1- M1T6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR|Nz65PEBvVQ>? MmPEV2FPT0WU
JAR NI\QXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHDdI5KSzVyPUSzPE43OiCwTR?= MXfTRW5ITVJ?
DSH1 M13wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHriWYlKSzVyPUS1PE46OSCwTR?= MUXTRW5ITVJ?
NCI-H187 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVqxTXBbUUN3ME20OlIvQDFibl2= MV;TRW5ITVJ?
HCE-4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrzVJNqUUN3ME20O|cvPjZibl2= NYn2V3l[W0GQR1XS
8-MG-BA M3r6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTV6MT61NkBvVQ>? NVPYeJE{W0GQR1XS
KLE MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3MN4lKSzVyPUW4OU4zKG6P NWTrTWZJW0GQR1XS
KNS-42 NY\teYQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTV6Nj64NUBvVQ>? NYLuXXg4W0GQR1XS
MSTO-211H MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLlTWM2OD14MEmuO|Qhdk1? MYLTRW5ITVJ?
GDM-1 NYLIZ3JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXFVHNCUUN3ME22NVQvODlibl2= NH\0U2tUSU6JRWK=
TE-1 NHPTWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLUTWM2OD14NE[uNVIhdk1? Mn\OV2FPT0WU
BT-474 NF\rR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3sUlNKSzVyPU[0O{4xPiCwTR?= M2HJfHNCVkeHUh?=
KARPAS-45 NWDvNmRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLhTWM2OD14NEeuOkBvVQ>? Mn;MV2FPT0WU
MOLT-16 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnITWM2OD14NEeuPVMhdk1? NXLpR5JYW0GQR1XS
KURAMOCHI MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS5TWM2OD14NUeuOVEhdk1? NXXMS3N3W0GQR1XS
K-562 NUDVcHdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO5e2JKSzVyPU[2PU42OSCwTR?= MmXzV2FPT0WU
EKVX Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK0TWM2OD14N{KuO|Ehdk1? MYTTRW5ITVJ?
GAK M17BSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPBTWM2OD14N{WuN{BvVQ>? NUjUZmw3W0GQR1XS
NCI-SNU-5 MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK1UmFGUUN3ME22PVAvODFibl2= NUDvZndoW0GQR1XS
NCI-H2126 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGzTWM2OD15Mk[uPFchdk1? M4Hr[XNCVkeHUh?=
CTV-1 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK2OVlKSzVyPUe0OE46KG6P NUPzdIFqW0GQR1XS
SW962 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor5TWM2OD15NEiuOFQhdk1? NIjQb|dUSU6JRWK=
MONO-MAC-6 M3XBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LBW2lEPTB;N{W2Mlk{KG6P NVnFRpNqW0GQR1XS
NCI-H748 NHPh[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTd3OD65PUBvVQ>? MVrTRW5ITVJ?
NCI-H524 M4\YTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fuRWlEPTB;N{iwMlc{KG6P MVvTRW5ITVJ?
LS-123 NVXzSIs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjrW5pKSzVyPUe5OU43QSCwTR?= M2jpN3NCVkeHUh?=
NB7 MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nJPWlEPTB;OEG0MlE1KG6P NYfpUW96W0GQR1XS
LS-1034 NYrFZo5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTh{OD65PEBvVQ>? MV\TRW5ITVJ?
TE-5 NUD2emZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTh6Mz61OkBvVQ>? NUH3bJh5W0GQR1XS
A704 NEjwXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWryWIVMUUN3ME24PVkvOTVibl2= NXjOS4ZLW0GQR1XS
TK10 NGjXepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjsO4lSUUN3ME25NVYvODNibl2= MnvrV2FPT0WU
NCI-H345 NEDyXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYexd295UUN3ME25OFMvOjJibl2= MXjTRW5ITVJ?
CGTH-W-1 NYD3cIhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD5XJRKSzVyPUm0PE4yOyCwTR?= Mm[0V2FPT0WU
NCI-H510A NHrkd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKzU2lKSzVyPUm4OU4yOiCwTR?= Mle5V2FPT0WU
NCI-H1963 NH\wcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwMEOyPVIh|ryP M1rJUnNCVkeHUh?=
SCC-3 NX3Zb2llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTHTWM2OD1zLkCzOFE1KM7:TR?= NHLwT4ZUSU6JRWK=
EW-11 NGjaeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmThTWM2OD1zLkC4O|Q{KM7:TR?= MlLWV2FPT0WU
CPC-N M3W5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwMEi4JO69VQ>? M2C0cHNCVkeHUh?=
NCI-H1417 M{LwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjpV2ZKSzVyPUGuNVIzPiEQvF2= MX7TRW5ITVJ?
DG-75 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\Ib3lRUUN3ME2xMlE3Ojh3IN88US=> NXrK[VlCW0GQR1XS
HD-MY-Z NVvNcpFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHNXWRKSzVyPUGuNVY1OTZizszN NFrkU|RUSU6JRWK=
ATN-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLSZ5o2UUN3ME2xMlI3OjB7IN88US=> MVrTRW5ITVJ?
KM-H2 M3\EXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwMk[0NFgh|ryP M3PqeHNCVkeHUh?=
NCI-H2081 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vPeWlEPTB;MT6yOlY{PyEQvF2= MkGzV2FPT0WU
HL-60 NVv6cYNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\DdmM6UUN3ME2xMlI3QTV7IN88US=> MmTYV2FPT0WU
DB MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwMkeyOFIh|ryP NIeyfZZUSU6JRWK=
NCI-H1522 M1;lNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Xuc2lEPTB;MT6yPFg5PyEQvF2= Mn\NV2FPT0WU
AM-38 NIDIb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnrNJJSUUN3ME2xMlMxPzJizszN NFnTNItUSU6JRWK=
NCI-H446 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwM{KxNlEh|ryP NGS3PXNUSU6JRWK=
SU-DHL-1 NIPNOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwM{K4NFEh|ryP NIfUXVBUSU6JRWK=
NH-12 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXVe2c6UUN3ME2xMlM3Ozd2IN88US=> MmnkV2FPT0WU
DMS-79 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH72b5lKSzVyPUGuN|Y5PjZizszN NIW5codUSU6JRWK=
NCI-H716 NV;kVmdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDQNnBZUUN3ME2xMlM5QTh4IN88US=> NVL6OppiW0GQR1XS
ML-2 NFfHXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFwNEG1Nlkh|ryP M3j6V3NCVkeHUh?=
NB10 M{jJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jCbWlEPTB;MT60OlY{OiEQvF2= NVPk[VVmW0GQR1XS
ONS-76 NFfBbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP2WFgxUUN3ME2xMlU{PTZ7IN88US=> NEf0XIRUSU6JRWK=
LOUCY M3r3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwNUS2OVch|ryP NIrwZWNUSU6JRWK=
SCLC-21H NXPTVYEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\vTnpKSzVyPUGuOVg2QDJizszN MXXTRW5ITVJ?
TGW NXXrSXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS4OZVSUUN3ME2xMlY{QTd3IN88US=> MVrTRW5ITVJ?
LXF-289 NHvLOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojZTWM2OD1zLkezNlY5KM7:TR?= NYrlXYFrW0GQR1XS
BB49-HNC NIDWWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K4N2lEPTB;MT63N|U5PiEQvF2= Mo\hV2FPT0WU
NCI-H747 NXy0WYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\wTWM2OD1zLke1N|Q3KM7:TR?= Mkf3V2FPT0WU
LU-165 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLKe|VKSzVyPUGuPFQ6QDZizszN NFT2enZUSU6JRWK=
OMC-1 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j4OGlEPTB;MT65OVA3PiEQvF2= M{fDfXNCVkeHUh?=
RCC10RGB NIrNSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrsTWM2OD1zLkm1PFE4KM7:TR?= NWPkOYl{W0GQR1XS
SW684 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\qS|dKSzVyPUGuPVYxQTlizszN MXrTRW5ITVJ?
TE-8 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;M[WlEPTB;Mj6wOVU2QSEQvF2= MlfIV2FPT0WU
SK-N-DZ MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln3TWM2OD1{LkGzNlc1KM7:TR?= MkHVV2FPT0WU
EVSA-T M{T0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJwMUezNVUh|ryP MlzLV2FPT0WU
KASUMI-1 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJwMUi4NVUh|ryP MX;TRW5ITVJ?
NKM-1 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP5cmVKSzVyPUKuNlU1PzJizszN NWG0RZI3W0GQR1XS
CAL-148 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXez[4RFUUN3ME2yMlM{PjF2IN88US=> MlvFV2FPT0WU
NCI-H64 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmzTWM2OD1{LkO0NlMzKM7:TR?= M4jETXNCVkeHUh?=
KNS-81-FD MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHOTWM2OD1{LkO2OlIh|ryP NEnROG9USU6JRWK=
KM12 NUjGd5ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwNEC4N|kh|ryP NGLJTXpUSU6JRWK=
SW954 M{Thfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfYTWM2OD1{LkS3O|c6KM7:TR?= NVLOflR1W0GQR1XS
NCI-H1395 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjlNHhKSzVyPUKuOVI3PDVizszN MVvTRW5ITVJ?
DJM-1 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwNkC2N{DPxE1? MnnrV2FPT0WU
COLO-668 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe5UpVKSzVyPUKuPFI3QTVizszN NYfrc4FSW0GQR1XS
NCI-H1436 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf5e4lPUUN3ME2yMlg2PjF3IN88US=> NYTQSoVQW0GQR1XS
LB2241-RCC NYO3WllqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Rb4l2UUN3ME2yMlg3QDN7IN88US=> MoO4V2FPT0WU
GT3TKB NHzYdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPiPIVCUUN3ME2yMlg6ODV3IN88US=> NWPTSZZXW0GQR1XS
COLO-824 M3XsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfu[HlKSzVyPUKuPFk4PjhizszN MVjTRW5ITVJ?
ES1 NEnscppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwOEm4O|kh|ryP Mor2V2FPT0WU
LB771-HNC MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLKTopKSzVyPUKuPVA6PDZizszN M3XWSnNCVkeHUh?=
GI-ME-N NIqyO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTNwMEC5NFQh|ryP MYrTRW5ITVJ?
NALM-6 NHXWVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\kSY9KSzVyPUOuNFA6OzNizszN NYDzc45lW0GQR1XS
LU-134-A NXfjbmdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy4cWpKSzVyPUOuNFU1OjVizszN NF3ONHdUSU6JRWK=
DMS-153 NHizXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;kTWM2OD1|LkC1PFI1KM7:TR?= NYTrW25UW0GQR1XS
MZ1-PC MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTNwMEmwO|gh|ryP M4rnbnNCVkeHUh?=
NCI-H1155 NHvyOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHmPYRbUUN3ME2zMlEyPjFizszN NIXXeolUSU6JRWK=
CAS-1 NV3IVGUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwMUO3NFch|ryP NHKxdIZUSU6JRWK=
D-502MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXZWZdKSzVyPUOuNVQ{QSEQvF2= MUHTRW5ITVJ?
NCI-H2141 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTndVZKSzVyPUOuNVc1PTJizszN NIm5ZZBUSU6JRWK=
NB6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTpTWM2OD1|LkG4NlU6KM7:TR?= NGDibZpUSU6JRWK=
NCCIT Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Oz[WlEPTB;Mz6yNVgxQSEQvF2= NIPrWI1USU6JRWK=
NB69 NEmzcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTNwM{G4PVEh|ryP NVS3[ZFZW0GQR1XS
JVM-2 NHjHOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTXTWM2OD1|LkO2OFM{KM7:TR?= NFfpS25USU6JRWK=
K052 M4rhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M375emlEPTB;Mz6zO|k3QCEQvF2= NGm4U5RUSU6JRWK=
HCC2157 NX3uOINIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrQTWM2OD1|LkWzNlI5KM7:TR?= M1rRPXNCVkeHUh?=
KMOE-2 MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNwNUSyOFIh|ryP MUHTRW5ITVJ?
SF268 NILHSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rmfmlEPTB;Mz63NVU2PCEQvF2= MoTHV2FPT0WU
CHP-126 NI\JeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CzdWlEPTB;Mz63OlQ2QCEQvF2= NX\LdYc5W0GQR1XS
CP66-MEL NV;ycWx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi4V5FNUUN3ME2zMlc6ODl2IN88US=> MoPYV2FPT0WU
NCI-H69 NVvuXFhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOwb|RKSzVyPUSuNFE6OzZizszN M4f2RnNCVkeHUh?=
A253 NHjkTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTRwMEKxNFEh|ryP M1e1W3NCVkeHUh?=
NB14 M3LxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33hWGlEPTB;ND6xNFQ4QSEQvF2= NXjLOVNHW0GQR1XS
NCI-H1694 NEPBNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLuWI9KSzVyPUSuNVMyOTJizszN MoTtV2FPT0WU
NCI-H2196 NYD0bm9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC3fm9KSzVyPUSuNVcyPjlizszN NXTQdo5oW0GQR1XS
TE-9 M4\nT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHBZ4E1UUN3ME20MlE4PTh{IN88US=> M17MTnNCVkeHUh?=
D-283MED M4\CU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fCZmlEPTB;ND6xPFg1KM7:TR?= MW\TRW5ITVJ?
OCI-AML2 NH7mRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DCfWlEPTB;ND6xPVQ5QSEQvF2= NXrZRXhRW0GQR1XS
D-263MG M1n1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37FN2lEPTB;ND6yNlk3OSEQvF2= Mk\CV2FPT0WU
MPP-89 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe3NlRbUUN3ME20MlI4OzB2IN88US=> M3HCbXNCVkeHUh?=
LAMA-84 NW\XdWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKxUnM6UUN3ME20MlMxPDJzIN88US=> MXLTRW5ITVJ?
LB373-MEL-D M4jhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3VZ3JKSzVyPUSuN|Y4QDlizszN MYLTRW5ITVJ?
UACC-257 M1j4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[4ZWN3UUN3ME20MlM6PTN2IN88US=> NX3PR4JYW0GQR1XS
MC-CAR NG\ZT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLiS2lKSzVyPUSuOFM6QSEQvF2= NVTSOnNOW0GQR1XS
COLO-320-HSR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTRwNES0Nlch|ryP NHnzOINUSU6JRWK=
P30-OHK MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fISWlEPTB;ND62OlU5OSEQvF2= MVPTRW5ITVJ?
UACC-812 NVPHdGJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjNZ|NKSzVyPUSuOlkyPjFizszN MYfTRW5ITVJ?
CTB-1 NGLQT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\DTGlEPTB;ND63NVU2PSEQvF2= NGC3ZpVUSU6JRWK=
ALL-PO MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHhTWM2OD12Lki0NFc4KM7:TR?= MV\TRW5ITVJ?
SK-MEL-2 NV3BRWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXSbohoUUN3ME20Mlg3QTV3IN88US=> MX7TRW5ITVJ?
TC-YIK NUn4WlJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPRR5FKSzVyPUSuPVc6PDJizszN MnvJV2FPT0WU
NCI-H1882 NGHheGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrGPZdKSzVyPUWuNFIxODFizszN MnLnV2FPT0WU
MHH-CALL-2 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTYTXJSUUN3ME21MlA2ODR{IN88US=> M3;Wd3NCVkeHUh?=
U-87-MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu1TWM2OD13LkC5OFY3KM7:TR?= M1HFfHNCVkeHUh?=
NCI-H1092 M3rVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXUS|djUUN3ME21MlI3PTV3IN88US=> NUnsPYVIW0GQR1XS
TE-441-T NV2wNVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXjdnNKSzVyPUWuNlc5OiEQvF2= M1m5WnNCVkeHUh?=
SK-MEL-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3kTWM2OD13LkK5NFQ1KM7:TR?= M4XSW3NCVkeHUh?=
EW-22 MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13FbWlEPTB;NT6yPVQ3PiEQvF2= NFKx[mdUSU6JRWK=
MZ7-mel MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTVwNEC2PVEh|ryP M2LpZ3NCVkeHUh?=
LP-1 NUTSdGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7sTWM2OD13LkSxNlkyKM7:TR?= MY\TRW5ITVJ?
NCI-SNU-16 M{Tmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\4eFdKSzVyPUWuOlQxPzRizszN NE\1[5BUSU6JRWK=
LU-65 NUnLemxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVwN{[zO|Mh|ryP NWmxVXUyW0GQR1XS
CW-2 NInSbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\PdnJZUUN3ME21Mlg2QTV7IN88US=> NVjNdnM{W0GQR1XS
WSU-NHL NF3wWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq5fIZsUUN3ME21Mlk2OTd2IN88US=> NV\6d5BoW0GQR1XS
IST-MES1 NGHadnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTVwOUW0OFMh|ryP MmPYV2FPT0WU
U-266 NIW4d41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zISGlEPTB;NT65PFIxOiEQvF2= M1HwXHNCVkeHUh?=
TALL-1 M1z4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTZwMUS2PFgh|ryP MVnTRW5ITVJ?
Calu-6 M{[w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTZwMUWzNVYh|ryP NV24NnlPW0GQR1XS
MMAC-SF Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnCTWM2OD14LkG4OVU3KM7:TR?= Mn\pV2FPT0WU
NCI-H82 NHzOeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK1fo4yUUN3ME22MlIxPDh7IN88US=> MVXTRW5ITVJ?
RS4-11 NFfqeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vpZWlEPTB;Nj6yOVg6PyEQvF2= M2G2U3NCVkeHUh?=
SNU-C2B NI\1WWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTZwNEC5Olkh|ryP MlW5V2FPT0WU
BOKU MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmroTWM2OD14LkS3OVk4KM7:TR?= NIXxUVJUSU6JRWK=
C8166 M1rWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfJTWM2OD14LkW1PVEzKM7:TR?= NFPiOWxUSU6JRWK=
D-247MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P3e2lEPTB;Nz6wOFM1PyEQvF2= MYjTRW5ITVJ?
EW-18 MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTdwMEeyPVIh|ryP NF3TcYtUSU6JRWK=
KG-1 M3jIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG0TWM2OD15Lk[yO|M5KM7:TR?= NULEeItnW0GQR1XS
REH NHHJWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTdwNkixNFkh|ryP M4rX[HNCVkeHUh?=
U-698-M MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjKXodDUUN3ME23Mlg1OzF3IN88US=> M{S3d3NCVkeHUh?=
KP-N-RT-BM-1 NInmNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXlenZKSzVyPUeuPVMxOjlizszN Mn7RV2FPT0WU
MS-1 NULG[XJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLaTWM2OD15Lkm2NFQyKM7:TR?= NIDPPYtUSU6JRWK=
SNU-C1 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULEU|JUUUN3ME23Mlk5OTl{IN88US=> M{m0SHNCVkeHUh?=
SK-MM-2 NWX5eJloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHEOmZvUUN3ME24MlI3ODZ3IN88US=> MXrTRW5ITVJ?
LAN-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DKS2lEPTB;OD6zNFAxOSEQvF2= MVLTRW5ITVJ?
NEC8 NYLF[29UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnRbY16UUN3ME24MlMxPjlzIN88US=> NIHlTplUSU6JRWK=
NCI-H1770 M3LuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4SyfWlEPTB;OD6zPFAxOiEQvF2= Mke5V2FPT0WU
D-336MG MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRThwNECxNVYh|ryP MmnvV2FPT0WU
COLO-829 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPITWM2OD16LkS4PFc6KM7:TR?= NUDyT3ZSW0GQR1XS
LS-513 NVjHcIJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRThwNUm1PVkh|ryP NFnnXoJUSU6JRWK=
YT NFzVTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRThwNkK0Nlch|ryP NVLJPZE3W0GQR1XS
EW-24 M2PTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRThwN{[1OEDPxE1? Mkf5V2FPT0WU
IST-SL1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRThwOE[1OFMh|ryP M4jrRXNCVkeHUh?=
CA46 NXvHR21QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRThwOUWwPVgh|ryP NXr2fI1QW0GQR1XS
NCI-H1838 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRThwOUi2NFIh|ryP MnHIV2FPT0WU
NCI-H719 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n3[mlEPTB;OT6yOVI4QSEQvF2= MX3TRW5ITVJ?
HCE-T MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPEbnhQUUN3ME25MlMxQDVzIN88US=> MXvTRW5ITVJ?
A498 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPiTWM2OD17LkO2NVI1KM7:TR?= NYLQeZpXW0GQR1XS
LB831-BLC NV3QXm9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXTTWM2OD17Lke2OVIyKM7:TR?= MV3TRW5ITVJ?
SKM-1 NEHvc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LSTGlEPTB;OT64OVk3OyEQvF2= NVXhO|l[W0GQR1XS
THP-1 NVnpOJFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzkTWM2OD17Lkm2PVE5KM7:TR?= Mne0V2FPT0WU
SHP-77 M2\MPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nzSGlEPTB;MUCuOFA4KM7:TR?= NWXiXpQ1W0GQR1XS
EW-3 M2jP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXnTWM2OD1zMD62Nlg6KM7:TR?= Mn:zV2FPT0WU
KY821 NXnVNY8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HwcWlEPTB;MUCuO|Y{KM7:TR?= NYjTOXVTW0GQR1XS
NCI-SNU-1 NH;oU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFzLkCyNVch|ryP NYnXOJJtW0GQR1XS
HCC2218 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OxcWlEPTB;MUGuN|k5PiEQvF2= NH2ySXBUSU6JRWK=
IM-9 M3ntZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fNVGlEPTB;MUGuOVExPiEQvF2= MVnTRW5ITVJ?
NCI-H889 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnVWmlKSzVyPUGxMlU{OTNizszN NWLYT4xEW0GQR1XS
HDLM-2 NHj2d4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnZXXhKSzVyPUGyMlQyPTlizszN MXnTRW5ITVJ?
LB2518-MEL NGHRdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrWO405UUN3ME2xNk43QDF3IN88US=> MnP3V2FPT0WU
NCI-H23 M3PvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzJTWM2OD1zMz6yOFI2KM7:TR?= M4XqRXNCVkeHUh?=
NB17 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PpTmlEPTB;MUOuOFU4QSEQvF2= NF7mdotUSU6JRWK=
NCI-H322M MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoruTWM2OD1zND60NFY5KM7:TR?= NWLVVGdHW0GQR1XS
SUP-T1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLhTWM2OD1zND60NVMh|ryP NVjDTJRyW0GQR1XS
ES3 NX\ubWhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn4TGNXUUN3ME2xOU4xPzB|IN88US=> MWLTRW5ITVJ?
ES5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6xcHpkUUN3ME2xOU4xPzh5IN88US=> NHTZUmRUSU6JRWK=
NCI-H1650 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTGOmpKSzVyPUG1MlQ6PzlizszN NHzEbVZUSU6JRWK=
NCI-H226 NEDXeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlKzTWM2OD1zNT64O|Y5KM7:TR?= Mn2zV2FPT0WU
COR-L88 NVy4d2c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jP[mlEPTB;MU[uN|E1KM7:TR?= MkP0V2FPT0WU
SCC-15 M{DIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i4bWlEPTB;MU[uN|g3QSEQvF2= NHnJN4tUSU6JRWK=
GOTO M1jaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF4LkS3PVMh|ryP NGLEN3ZUSU6JRWK=
SIMA NIfUZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\2TWM2OD1zNj60PFAzKM7:TR?= MYnTRW5ITVJ?
NCI-H1299 NXn0NXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\HUndQUUN3ME2xO{4yPTlzIN88US=> NWjHemZoW0GQR1XS
NCI-H1581 NV21S5FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrMTWM2OD1zNz60NlE6KM7:TR?= MlqyV2FPT0WU
MHH-NB-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Ht[2lEPTB;MUeuPVY5OyEQvF2= M2CzOXNCVkeHUh?=
MFM-223 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF6LkC1N|gh|ryP NX\XZ4FWW0GQR1XS
ES7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfoZnBKSzVyPUG4MlU1OzFizszN NFXyWZhUSU6JRWK=
JVM-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfCeIxKSzVyPUG4MlcyPyEQvF2= NHm3XIZUSU6JRWK=
RL MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTITWM2OD1{MD6zPFgh|ryP NGqyfWtUSU6JRWK=
EC-GI-10 M2rDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrUTWM2OD1{MT6yNFQyKM7:TR?= NH35UWFUSU6JRWK=
LNCaP-Clone-FGC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJzLk[3Olgh|ryP M37ZXXNCVkeHUh?=
IMR-5 M{m4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWeyfIpIUUN3ME2yNU45PDl2IN88US=> MYTTRW5ITVJ?
KP-N-YS NUC3ZpFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJzLki3OUDPxE1? NYe4dWxvW0GQR1XS
Mo-T NHnYRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPXVVlKSzVyPUKyMlIyQDVizszN M1\yOHNCVkeHUh?=
NCI-H128 MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ|LkW4OVMh|ryP NWm4WIxVW0GQR1XS
RH-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[5NFJKSzVyPUKzMlc5PjZizszN NXf5eVF6W0GQR1XS
NCI-H2171 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ2LkK0PFUh|ryP M4Xyb3NCVkeHUh?=
RPMI-8866 NHniUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXaUllDUUN3ME2yOk44PDJizszN MVjTRW5ITVJ?
SK-N-FI MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fabmlEPTB;MkeuN|gyOSEQvF2= MnzBV2FPT0WU
LOXIMVI Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn1Rmp2UUN3ME2yO{45ODVzIN88US=> MY\TRW5ITVJ?
P31-FUJ NV7hOHpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK1cY5KSzVyPUOxMlU{PzRizszN NF\Xb4tUSU6JRWK=
KMS-12-PE MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR7LkWzNFIh|ryP MV\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID